New smart drug targets cancer cells in advanced tumors

NCT ID NCT04064359

Recruiting now Disease control Sponsor: Oxford BioTherapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests OBT076, a drug that combines an antibody with a chemotherapy agent to target and kill cancer cells that have a specific protein called CD205. The study includes up to 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also looking at whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OBT076 (an antibody-drug conjugate that targets CD205 on cancer cells and delivers a chemotherapy drug)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial, so the drug may not work or could cause serious side effects. It is only tested in a small number of people, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

AZ Groeninge
COMPLETED

Kortrijk, Belgium
Cedars-Sinai
COMPLETED

Los Angeles, California, 90048, United States
Centre Eugène Marquis
RECRUITING

Rennes, France
Columbia University Medical Center
COMPLETED

New York, New York, 10032, United States
EuroMedica
COMPLETED

Thessaloniki, GR-54645, Greece
GHP Saint-Joseph
RECRUITING

Paris, France
Hopital Saint Antoine
COMPLETED

Paris, France
Hopital Saint Louis
RECRUITING

Paris, France
Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
ICANS - Institut de cancérologie Strasbourg
RECRUITING

Strasbourg, France
Institut Gustave Roussy - IGR
RECRUITING

Villejuif, France
Institut Jules Bordet
RECRUITING

Brussels, Belgium
Institut Paoli Calmettes
RECRUITING

Marseille, France
Mayo Clinic
COMPLETED

Phoenix, Arizona, 85084, United States
Metropolitan Hospital
COMPLETED

Athens, Greece
Moffitt Cancer Center
COMPLETED

Tampa, Florida, 33612, United States
Quantum Santa Fe
COMPLETED

Santa Fe, New Mexico, 87505, United States
START Barcelona HM Nou Delfos
RECRUITING

Barcelona, 08023, Spain
Sotiria General Hospital
RECRUITING

Athens, Greece
St. Elizabeth Healthcare
COMPLETED

Edgewood, Kentucky, 41017, United States
The State University of Iowa
ACTIVE_NOT_RECRUITING

Iowa City, Iowa, 52242, United States
UCLA
COMPLETED

Santa Monica, California, 90404, United States
University General Hospital Attikon
RECRUITING

Chaïdári, Athens, 12462, Greece
University General Hospital of Heraklion
RECRUITING

Heraklion, Greece
University Hospital Marqués de Valdecilla
RECRUITING

Santander, 39008, Spain
University of Mississippi Medical Center
COMPLETED

Jackson, Mississippi, 39216, United States
University of Pittsburgh
COMPLETED

Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.